GlassScriptPhysician profile
Aaron Z Cohen
NPI 1639464019
$2,878.44
in general payments reported to CMS, 2019-2025
34 companies · $852 in 2025
The $852 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $159 · 2021: $380 · 2022: $376 · 2023: $282 · 2024: $657 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $284.91 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $272.10 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $223.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $199.25 | 2020-2025 | Krystexxa, Repatha, Repatha |
| Abbott Laboratories | $182.65 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.36 | 2024-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $179.00 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $143.17 | 2021-2025 | Airsupra |
| Pfizer INC. | $140.05 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $92.68 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $73.33 | 2019-2022 | |
| Abbvie INC. | $65.45 | 2021-2025 | Vraylar |
| Boston Scientific Corporation | $56.80 | 2019-2024 | Watchman Flx |
| Medtronic, INC. | $52.33 | 2024 | Intellis Adaptivestim |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.80 | 2022-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $49.80 | 2025 | |
| Smith+Nephew, INC. | $43.81 | 2024 | Or3o Dual Mobility, Real Intelligence |
| Corcept Therapeutics | $28.14 | 2025 | Korlym |
| Philips North America LLC | $24.66 | 2019 | |
| Biosense Webster, INC. | $22.77 | 2022 | |
| Solventum Corporation | $22.05 | 2025 | V.A.C.Instill, Abthera Advance, V.A.C. Veraflo |
| Otsuka America Pharmaceutical, INC. | $21.18 | 2024 | Rexulti |
| Eisai INC. | $20.53 | 2025 | |
| Redhill Biopharma INC. | $20.07 | 2020 | |
| Gilead Sciences, INC. | $18.30 | 2020 | |
| Hologic Sales and Service, LLC | $16.69 | 2020 | |
| Sobi, INC | $15.72 | 2019 | |
| Amarin Pharma, INC. | $15.59 | 2022 | |
| Dexcom, INC. | $14.79 | 2024 | Dexcom G6 Transmitter |
| Medexus Pharma, INC. | $12.23 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.